years. Forty-three of these patients had chronic glom-Introduction erulonephritis as the underlying renal disease. Patient characteristics including plasma levels of lipids and Renal insuÃciency is associated with specific abnorapolipoproteins were determined at entry and were malities in the lipoprotein metabolism both in the early prospectively related, using linear regression, to the and in the advanced stages of chronic renal failure rate of progression.
[1-3 ]. The clinical significance of renal dyslipoprotei-Results. The mean GFR at entry was 41.3 (SD naemia is, however, not yet clearly established [4] . The 15.3) ml/min×1.73 m2 BSA. The average rate of prorenal dyslipoproteinaemia may contribute not only to gression was a decline in GFR of −2.8 (SD an accelerated development of atheroclerosis [4-7 ] but 3.7) ml/min×1.73 m2 BSA per year. In the whole also to the progression of human chronic renal failure patient study group total cholesterol, low-density lipo- [8, 9] . Studies on the experimental renal insuÃciency protein ( LDL) cholesterol, and apolipoprotein B clearly indicate that hyperlipidaemia exerts a nephro-(apoB) were all significantly associated with a more toxic eÂect and accelerates glomerulosclerosis [4, 7] . A rapid decline in renal function, whereas triglycerides, few observations in human chronic renal failure in high-density lipoprotein ( HDL) cholesterol, and both diabetic [10-12] and non-diabetic [13, 14] patients apolipoprotein A (apoA ) were not. In the more support the hypothesis of lipid nephrotoxicity [8] . In homogeneous subgroup of patients with chronic gloma previous retrospective study we have shown that the erulonephritis the association between dyslipidaemia plasma level of apolipoprotein (apo) B was associated and the rate of progression was even more pronounced.
with the rate of progression of renal insuÃciency [15 ] . In this subgroup of patients also serum triglycerides Based on these observations we initiated a prospective and apoE were significantly associated with a higher study in 1990 with the principal objective to evaluate rate of progression. Both the initial blood pressure and the prognostic impact of renal dyslipoproteinaemia on the rate of progression of human chronic renal insuÃ-
Patient population Lipid and lipoprotein determinations
From 1990 to the end of 1991, 77 patients with chronic primary renal disease and a glomerular filtration rate (GFR) At the beginning of the study and at regular 6-month between 15-75 ml/min×1.73 m2 body surface area (BSA) intervals during follow-up, venous blood samples were drawn were included in a prospective, observational study for a into EDTA-containing vials for measurements of plasma planned duration of 3 years. The patients were recruited lipids and apolipoproteins after an overnight fast and anafrom five nephrology clinics in Sweden. Patients with diabetes lysed in the fresh state. Plasma lipid concentrations were mellitus or patients treated with any type of immunosuppresdetermined enzymatically and the plasma concentrations of sive therapy or lipid-lowering agents were excluded. No apolipoproteins by electroimmunoassays as previously dietary advice counselling regarding protein or energy intake described [1 ] . The high-density lipoprotein ( HDL) choleswas given to the patients prior to and during the follow-up terol levels were determined as previously described [ 1]; veryperiod of observation. During the first 12 months of followlow-density lipoprotein ( VLDL) and low-density lipoprotein up, four patients were withdrawn from the study because of (LDL) cholesterol levels were calculated according to the death (n=3) or living donor transplantation (n=1).
Friedewald formula [17] . The distribution of apolipoprotein Forty-three (59%) of the patients had chronic glomerulo-C-polypeptides among lipoproteins was determined by measnephritis, 11 (15%) had interstitial nephritis, eight ( 11%) had uring apoC-III in heparin Mn++ supernates (i.e. in 'HDL'), adult polycystic kidney disease, and eight (11%) had apoC-III-HS, and precipitates (i.e. in 'VLDL+LDL'), apoCnephrosclerosis as the underlying chronic renal disease. In III-HP. The lower the ratio between these two the less the remaining three patients the primary renal disorder could eÃcient is the removal of triglyceride-rich lipoproteins [ 4] . not be adequately diagnosed. There were 16 females and 57
To reduce intraindividual variability, the mean value of the males. The mean age was 49.4 (SD 12.8) years (range 21-69 measurements during the first 6 months of observation were years). Table 1 presents the patient characteristics at baseline used as the baseline value for lipoprotein variables. of the study in all patients (n=73) and in the subgroup of patients with chronic glomerulonephritis (n=43). In the whole study group the mean total urinary protein and the Other clinical variables urinary albumin excretion were 2.1 (SD 2.4) g/24 h and 1.4 (SD 1.6) g/24 h respectively, with median (and range) values Serum parathyroid hormone levels were determined at the of 1.9 g/24 h ( 0.02-11.5) and 1.1 g/24 h (0.01-6.8). Thus the entry and was measured as intact PTH. Entry BP was distribution of these two variables were highly skewed. This recorded after 5 min supine rest. Twenty-four hour urinary was also the case for the serum levels of parathyroid hormone protein excretion was measured at the beginning of the study ( PTH) with a median value of 56.5 ng/l, ranging from 10 to and then at 6-months intervals. To reduce intraindividual 103 ng/l. Seventeen patients had a urinary protein excretion variability of urinary protein excretion, the mean values rate exceeding 3.0 g/24 h but none of the patients had obtained during the initial 6 months of observation were oedema; only one patient, with a urinary protein excretion used as baseline values. In the whole study group measurerate of 8.2 g /24 h at baseline, had subnormal serum albumin ment of 24-h urinary protein excretion was done in 67 levels. The baseline characteristics in the patients with chronic patients. Due to diÂerent routines in the five participating glomerulonephritis as the underlying renal disease did not hospitals, both 24-h urinary total protein and 24-h urinary diÂer from those in the other group of patients ( Table 1 ) .
albumin excretion were determined in 51 patients. In 12 Sixty-four (88%) of all patients were on antihypertensive patients only the 24-h albumin excretion was determined. treatment at start of the study. Forty-five patients (62%) Because the correlation between the total urinary protein were treated with an ACE inhibitor, and 15 patients (21%) and albumin excretion was very high in the patients who with a calcium antagonist. The corresponding treatment had simultaneous measurements (r=0.98, P=0.001, linear frequencies for diuretics and beta-blockers were 35 (48%) regression) the total 24-h urinary protein excretion was and 34 ( 47%) respectively. Among patients with chronic calculated for the 12 patients with only albumin excretion glomerulonephritis 40 ( 91%) were receiving antihypertensive determined at the beginning of the study. treatment. Twenty-seven (68%) of them were treated with an ACE inhibitor and nine ( 21%) with a calcium antagonist. Analysis of data and statistical methods
The antihypertensive treatment was stable during the study with few individual changes in the therapeutic profile. Thus Standard statistics were used to illustrate the salient features the frequencies of ACE inhibitor treatment after 12 and 24 of the data. The association between baseline values and the months of observation were 58 and 65%. The corresponding rate of progression (slope of GFR) was analysed both by treatment frequencies for calcium antagonists were 27 and linear regression analysis and Spearman's rank correlation 29% respectively. test. Because there was no qualitative diÂerence between these methods of analyses only the former are presented.
Only P values less than 0.05 were considered as statistically
Renal function significant. The potential confounding eÂect of relevant background variables was analysed using multiple linear Glomerular filtration rate was determined as the plasma or renal clearance of 51Cr-EDTA according to established pro-regression. The lipid variables of interest (see Results) were divided into tertiles of their respective baseline levels, i.e. cedures [16 ] . The renal clearance method was used when the GFR was below 20 ml/min/1.73 m2 BSA. Glomerular filtra-divided into 'low', 'intermediate' and 'high' levels, to illustrate the rate of progression and other patient characteristic tion rate was determined initially, and at 3-month intervals in 35 patients and at 6-month intervals in 38 patients. The variables.
The analyses were performed in all patients, i.e. the whole individual rate of progression of renal insuÃciency was study group, and separately in the subgroup of patients with significantly associated with the rate of progression. chronic glomerulonephritis as the underlying renal disease. The initial level of apoB correlated also significantly The numbers of patients with other underlying diagnoses of with a more rapid decline in GFR as illustrated in the primary chronic renal disease were too low to allow any Figure 1 . However, within the whole group of patients meaningful further subgroup analyses.
there was no significant relation between triglycerides, VLDL cholesterol, apo C-III, apoE or HDL-related variables (HDL cholesterol, apo AI, apo AII, apoC-Results III-HS ) and the rate of progression. Tables 2 and 3 present the rate of progression and the baseline patient All patients characteristic variables according to 'low', 'intermediate' and 'high' initial plasma levels, i.e. in tertiles, The mean GFR value at entry was 41.3 (SD of LDL cholesterol and apoB respectively. 15 .3) ml/min/1.73 m2 BSA. The patients were followed
The levels of LDL cholesterol and apoB were for an average of 3.2 (SD 0.7) years (range 1.0-4.0), significantly correlated (r=0.85, P=0.0001). The and the mean rate of progression in the whole patient significant associations between the initial levels of the population during the follow-up was −2.8 (SD respective lipoprotein variables (total cholesterol, LDL 3.7) ml/min/1.73 m2 BSA per year. There was a wide cholesterol, apoB) and the change in renal function interindividual variation in the progression rate ran-(i.e. slope of GFR) were all independent of the GFR ging from +4.7 to −13.8 ml/min/year. In fact 17 value at the entry. ( 23%) of the patients did not show any further decrease
The initial values of BP and the 24-h urinary protein or even had an increase in GFR during the observaexcretion rate were also significantly associated with tion period.
the rate of progression ( Table 1) , independently of the Table 1 presents the results of the linear regression GFR value. Table 4 presents the 24-h urinary protein analyses relating the patient characteristic variables at and albumin excretion rates and the serum albumin baseline with the rate of progression. From the correlalevels during follow-up. It is evident that the degree of tion coeÃcients it is evident that some of the plasma proteinuria did not change during the study period. lipids and apolipoprotein variables were associated
The associations of the baseline levels of LDL choles-with a higher rate of progression. The initial total cholesterol and LDL-cholesterol levels were both terol and apoB respectively, with the progression rate ii. Apo C-III HS is the Apo C-III in heparin-Mn2+ supernate ('HDL') and Apo C-III HP is the Apo C-III in heparin-Mn2+ precipitate ('VLDL+LDL'). These variables reflect the distribution of ApoC-polypeptides among the lipoproteins (see also text).
were both independent of the initial BP level. This was the case regardless of whether systolic or diastolic BP were used in the regression model. The association between LDL cholesterol and the rate of progression was also independent of the baseline 24-h urinary protein excretion. The apoB level was, however, not independently associated with the progression rate when the contribution of proteinuria was accounted for, although there was a strong trend for such a relationship (P=0.06). When the patient population was divided into four groups using the median value of systolic BP (cut-oÂ point 140 mmHg) and the median value of apoB (cut-oÂ point 145 mg/ml ) it was found that patients with both a high systolic BP and a high plasma concentration of apoB (n=20) had an almost four times higher progression rate (a slope of GFR of −5.1 ml/min/1.73 m2 BSA per year) than 16 patients with a low baseline systolic BP and lower apoB levels (a slope of GFR of −1.4 ml/min/1.73 m2 BSA per year) (P<0.001). Figure 2 illustrates the high rate of progression (a slope of GFR of −5.9 ml/min/1.73 m2 BSA per year) that was observed in the patients with with chronic glomerulonephritis (n=43). The average time of follow-up was 3.0 (SD 0.6) years and the mean rate of progression was −3.1 (SD 4.1) ml/min/1.73 m2 BSA per year (range −13.8 to +4.6).
As in the whole study group, it is evident that patients with chronic glomerulonephritis with a higher rate of progression diÂered in their plasma lipids and apolipoprotein pattern from patients with a more stable renal function ( Table 1 ). If anything, the correlation coeÃcients between the lipid and apolipoprotein variables of interest were higher than in the whole patient study group. Similar to the findings in all patients, higher plasma levels of total and LDL cholesterol and higher plasma concentrations of apoB were significantly associated with a higher rate of progression. Also the baseline levels of triglycerides and apoE were significantly associated with a more rapid decline in renal function. Furthermore, ApoC-III HP tended to be associated with the rate of progression (r=0.28, P=0.07).
Blood pressure and proteinuria were significantly ( Table 1 ) pendently of one another associated with the rate of progression. antly (P<0.001) from the progression rate observed in patients with lower LDL cholesterol combined with Discussion a lesser degree of urinary protein excretion (n=30).
When separately analysed in patients within baseline The main finding of this prospective study was that GFR values between 25 and 50 ml/min/1.73 m2 BSA lipoprotein abnormalities characteristic of renal dysli-(n=41) the qualitative outcome of the analyses were poproteinaemia [4 ] were significantly associated with very similar to that in the whole patient population the rate of progression of renal insuÃciency. This was (data not given). Furthermore the correlation coeÃobserved in the whole study group as well as in the cients for the lipoprotein variables changed minimally major subgroup of patients with chronic glomerulowhen the patients with a 24-h protein excretion above nephritis. The outcome of the present study confirms 3.0 g per 24 h (n=17) were excluded from the analyses and extends our previous observation in a retrospective (data not given).
study [15] showing that elevated levels of apoBcontaining lipoproteins seem to be of prognostic Patients with chronic glomerulonephritis importance in patients with progressive chronic renal insuÃciency. The mean GFR at entry was 41.1 (SD 15.2) ml/min/1.73 m2 BSA in the group of patients
The patient population in this study is representative of unselected adult subjects with a moderately role of renal dyslipidaemia is investigated. The importance of apolipoprotein profiling is based on the notion advanced renal insuÃciency from non-diabetic renal disease. The lipid and apolipoprotein profiles of the that apolipoproteins are the essential constituents responsible for the functional properties and structural study group corresponded to those previously reported in patients with moderate renal insuÃciency stability of circulating lipoprotein particles [29] .
In our previous smaller study elevated serum tri-[1-3, 18, 19] characterized by abnormalities in the apolipoprotein rather than the lipid profile. This character-glyceride and VLDL cholesterol levels were associated with a more rapid decline in GFR [15 ] . In the present istic profile reflects increased concentrations of intact or partially metabolized apoB-containing lipoproteins study such an association was found only in the patients with chronic glomerulonephritis but not in the and reduced concentrations of apoA-containing lipoproteins [4 ] . entire patient population. However, LDL cholesterol levels were significantly associated with a higher rate The study was a long-term observational study. It was based on previous retrospective as well as cross-of progression in both the chronic glomerulonephritis group of patients as well as in the whole patient study sectional studies suggesting that lipoprotein abnormalities may play a role in the progression of renal group. Since the LDL cholesterol was calculated by the Friedewald formula, the estimated LDL cholesterol insuÃciency. To further explore such a temporal relationship a prospective design was necessary. It was also includes lipoproteins of the intermediate density density range ( IDL). Hence, these associations indicate also essential that the glomerular filtration rate was measured repeatedly by reliable methods during a that increased concentrations of apoB-containing lipoproteins in the IDL-LDL range may play an important suÃciently long follow-up [20] . These requirements have been met in the present study. All patients have role in the progression of primary renal disease.
One of the main characteristics of renal dyslipo-been closely monitored during follow-up and managed according to recommended and widely accepted treat-proteinaemia is the accumulation of intact and partially metabolized apoB-containing lipoproteins [4 ]. ment strategies [21] . More than 80% of patients were on active antihypertensive drug therapy with most Depending on the state of delipidization, the triglyceride content may vary resulting in lipoproteins of IDL patients receiving an ACE inhibitor.
Although patients with chronic renal disease fre-and/or LDL density range. The findings in the present study show that increased concentrations of apoB-quently show a progressive course of renal insuÃciency [22, 23] , the notion that it is inevitable is not supported containing lipoproteins may be associated with more rapid progression of renal insuÃciency through inter-by data in this and other studies [24] [25] [26] [27] . About onequarter of our patients had stable or even improved action of these potentially atherogenic lipoproteins [30] with glomerular and/or tubulointerstitial tissue. The renal function during the observation period.
The risk-factor pattern for progression of chronic possible importance of these lipoprotein abnormalities for the sclerotic processes is further highlighted by the renal insuÃciency may diÂer to some extent in diÂerent renal disease categories [24, 28] . Due to the limited finding of accumulation of cholesterol, LDL-cholesterol and apoB in both sclerotic and non-sclerotic number of patients with diÂerent underlying renal diagnoses the present study allowed a meaningful risk-glomeruli of patients with various renal diseases [31] [32] [33] [34] [35] . Recently it has also been demonstrated that factor analysis only in the subgroup of patients with chronic glomerulonephritis. glomerular cells have the LDL receptor [36 ] and that both mesangial cells and glomerular epithelial cells For many patients with progressive renal disease, therapy is currently limited to intervention against show a marked ability to take up and internalize lipoproteins of intermediate density (i.e. IDL) by recep-amenable factors that may accelerate progression of the renal insuÃciency per se. In a recent observational tor-mediated and non-receptor-mediated pathways [37, 38] . study by Jungers et al., of a patient population similar to ours [28] , it was shown that the type of nephropathy, An important question is whether renal dyslipoproteinaemia also contributes to accelerated atherosclerosis proteinuria and gender were all three independently predictive of progression. However, these three risk in renal patients. Many reports indicate that this may be the case [6 ] . The lipid and apolipoprotein pattern factors could together only account for about onethird of the variation in the rate of decline in renal in patients with the highest rate of decline in renal function (data not given) were similar to those charac-function. They also found that the alterable factors blood pressure and protein intake, only had a modest teristic of accelerated atherosclerosis in patients without renal disease [39, 40] . Of particular interest is that influence on the progression.
Most studies in human progressive chronic renal partially degraded triglyceride-rich apoB-containing lipoproteins are strongly associated with the develop-disease have focused on the prognostic impact of elevated plasma lipids, i.e. of hypercholesterolaemia ment of small coronary atherosclerotic lesions [41 ] .
One may speculate that these apoB-containing lipopro-[10-13]. However, the present findings confirm that renal dyslipoproteinaemia is predominantly reflected teins that accumulate in renal insuÃciency [4 ] may be responsible for damaging eÂects both on the arterial in an abnormal apolipoprotein rather than lipid profile [4 ] . Therefore it is necessary to analyse the specific wall [30, [42] [43] [44] and on the glomerular and tubular structures of the diseased kidney. lipoprotein abnormalities not only in terms of lipid but also in terms of apolipoprotein profiles when the Hypertension is a well-established risk factor for progression of renal insuÃciency [21] [22] [23] 45, 46 ] . The sion of renal insuÃciency. At present it is not known to what extent lipid-lowering treatment can attenuate results of the present study are in agreement with these findings, showing that despite the antihypertensive the rate of progression. Therefore, a lipid-lowering clinical trial in patients with moderate to advanced treatment, an elevated BP remains associated with a more rapid rate of progression. The association renal insuÃciency is needed to clarify whether normalization of the renal dyslipoproteinaemia will result between apoB-containing lipoproteins and the decline in renal function was, however, independent of the BP in an improved renal prognosis for patients with progressive renal failure. levels. As in our previous retrospective study [15 ] we found that patients with both high systolic BP and
